US Medicare has set a national outpatient payment of US$31,265 for Epiminder’s Minder System implant procedure from 1 January 2027, up 13% on the 2026 rate. The decision gives hospitals a defined reimbursement benchmark ahead of Epiminder’s planned US commercial launch.
- US$31,265 national Medicare payment for the Minder implant procedure in CY2027
- 13% increase from the US$27,700 rate set for 2026
- Payment applies from 1 January 2027 and covers the hospital outpatient procedure, including the implanted device
- DETECT study enrolment reaches 100 participants, with 125 targeted by December 2026
- Expanded paediatric FDA clearance adds to Epiminder’s commercialisation push
Medicare sets US$31,265 Minder payment
Epiminder Limited (ASX:EPI) has cleared a significant commercial hurdle in the United States, with Medicare assigning its Minder System implant procedure a national outpatient payment of US$31,265 for calendar 2027. The rate, set under the Hospital Outpatient Prospective Payment System in Ambulatory Payment Classification 5117, is 13% above the US$27,700 rate for 2026 and takes effect on 1 January 2027.
The payment is designed to cover the hospital’s costs for the outpatient procedure, including the implanted device, although the final amount will be adjusted for local wage levels at each hospital. For Epiminder, the significance is less a disclosed revenue forecast than the establishment of a defined reimbursement reference point for hospitals assessing whether to introduce the minimally invasive subscalp implant.
Reimbursement follows DETECT recruitment and FDA clearance
The decision arrives as Epiminder builds towards a US commercial launch. Earlier coverage recorded the company’s proposed Medicare increase for 2027, while the final determination has now put a specific national payment behind that proposal.
Epiminder said the 2027 payment determination also builds on an expanded paediatric FDA clearance issued the previous week and the enrolment of the 100th participant in its DETECT study. That milestone was reported in 100th DETECT enrolment, and the company expects to reach 125 participants by December 2026.
Hospital adoption remains the next commercial test
Chief executive Rohan Hoare said hospitals need certainty about how a new technology will be paid for when used for Medicare beneficiaries. Chip Moebus, Epiminder’s vice-president of market access and commercial, described the ruling as the cornerstone of hospital outpatient reimbursement and said the rate should give hospital finance and value analysis teams greater predictability.
The filing does not quantify expected sales, margins, procedure volumes or the timing of hospital uptake. The next evidence will therefore come from execution: whether US epilepsy centres adopt Minder, how many procedures are performed, and how realised reimbursement compares with the national benchmark once local adjustments are applied.
Bottom Line?
The reimbursement rate removes one important barrier to US hospital evaluation, but commercial traction will depend on real-world adoption and procedure volumes from 2027.
Questions in the middle?
- How many US hospitals will begin using Minder once the payment takes effect?
- What procedure volumes and realised reimbursement will Epiminder report during the commercial launch?
- Can DETECT enrolment reach 125 participants by December while the company prepares its US rollout?